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Available online 8 June 2017Background: The angiogenesis in systemic sclerosis (SSc) is impaired. An imbalance of pro-angiogenic factors and
angiogenesis inhibitors has been implicated in the progression of peripheral microvascular damage, defective
vascular repair and fibrosis. Intrarenal resistance index are considered markers of renal vasculopathy. The aim
of the study is to evaluate angiogenic and angiostatic factors (VEGF and endostatin) in SSc patients and to corre-
late with intrarenal hemodynamic parameters.
Methods: 91 SSc patients were enrolled in this study. Serum VEGF and endostatin levels were determined. All
patients underwent a renal Doppler ultrasound
Results: A significant positive correlation was observed between endostatin and renal Doppler parameters
(p b 0.0001). A negative correlation was observed between serum levels of endostatin and eGFR (p b 0.01). In
SSc patients with high resistive index, serum levels of endostatin were significantly (p b 0.01) higher than in
SSc patients with normal resistive index. The serum levels of endostatin significantly increased with progression
of nailfold videocapillaroscopy damage (p b 0.01) and were significantly (p b 0.05) higher in SSc patients with
digital ulcers than in SSc patients without digital ulcers.
Conclusion: This is the first study that assess in SSc patients intrarenal hemodynamic parameters and endostatin.
In SSc patients, endostatin represents a marker of renal scleroderma-associated vasculopathy.






Systemic sclerosis (SSc) is a connective tissue disease characterized
by vasculopathy, collagen deposition and fibrosis in the skin and inter-
nal organs. In SSc the endothelial dysfunction is the most important
feature and involves both the macro and microvasculature (Campbell
and LeRoy, 1975).
The progressive derangement of themicrocirculation leads to a state
of chronic tissue hypoxia that stimulates the release of angiogenic
growth factors such as vascular endothelial growth factors (VEGF).inhibitors; CKD, chronic kidney
eous SSc; DSS, Disease Severity
ate rate; HC, healthy controls;
total skin score; NVC, Nailfold
ary arterial hypertension; PI,
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ared.
edicine, Sapienza University of
te).Conversely, the inhibitors of angiogenesis are represented by endostatin
and angiostatin (Hummers et al., 2009).
Several forms of renal damage are recognized in patients with SSc,
from asymptomatic reduction of glomerular filtrate rate (GFR), reduced
renal functional reserve, microalbuminuria and increased intrarenal ar-
terial stiffness to renal scleroderma crisis (Shanmugam and Steen,
2010).
The association of renal dysfunction and vasculopathy is common in
SSc and usually exhibits a benign course.
Regardless of SSc, chronic kidney disease (CKD) presents a defective
angiogenesis with high levels of endostatin and reduced VEGF (Futrakul
et al., 2008). The aim of the study is to evaluate two angiogenetic and
angiostatic factors, such as VEGF and endostatin, in SSc patients and to
correlate with intrarenal hemodynamic parameter.
2. Methods
91 patients (80 female and 11 male; mean age 54.4 ± 13.3 years)
fulfilling the American College of Rheumatology/European League
criteria for classification of SSc were enrolled in this study (van den
Hoogen et al., 2013).
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fuse cutaneous SSc (dcSSc) as defined by LeRoy et al. (1988).
All SSc patients underwent treatmentwith calcium channel blockers
(nifedipine 30 mg/day). None of patients were treated with immuno-
suppressive agents (e.g. cyclophosphamide or mycophenolate mofetil),
angiotensin-converting enzyme inhibitors (ACE-I), angiotensin II recep-
tor blockers, diuretics or xanthine oxidase inhibitors.
Patients with urinary tract infections, abnormal urinary sediment,
glomerulonephritis, acute and chronic kidney disease, scleroderma
renal crisis, kidney stones, anti-phospholipid-associated nephropathy,
diabetes, cardiovascular diseases such as hypertension, myocardial in-
farction, arrhythmias, heart failure, hyperlipidaemia, coagulopathy,
obesity or smokers were excluded.
48 healthy controls (HC) (42 female and 6 male; mean age 49.7 ±
15.3 years) were also enrolled in this study.
The subjects'written consentwas obtained according to theDeclara-
tion of Helsinki and the study was approved by ethics committee of
Sapienza University (IRB approval 377/2014).
2.1. Laboratory parameters
Laboratory investigations included serum creatinine (sCr) (normal
range: 0.5–0.9 mg/dl), blood urea nitrogen (normal range: 10.20–
49.80 mg/dl), serum uric acid (UA) (normal range: 3.40–7.20 mg/dl),
urinalysis and 24 h proteinuria. sCr was measured using a Jaffe alkaline
picrate assay (Abbott Aeroset analyser) (Wetzels et al., 2007). SerumUA
wasmeasured with an automatic analyzer (7700 series; Hitachi, Tokyo,
Japan).
2.2. Calculation of GFR
GFRwas calculated using the CKD-EPI equation, already validated in
SSc (Gigante et al., 2012), expressed as a single equation: GFR= 141 ×
min (sCr/k, 1) α × max (sCr/k, 1)−1.209 × 0.993 Age × 1.018 (if
female) × 1.159 (if black), where k is 0.7 for females and 0.9 for
males, α is −0.329 for females and −0.411 for males, min indicates
the minimum of sCr/k or 1 and max indicates the maximum of sCr/k
or 1 (Levey et al., 2009).
2.3. Nailfold videocapillaroscopy
Nailfold videocapillaroscopy (NVC) was performed with a
videocapillaroscope (Pinnacle Studio Version 8) equipped with a 500
× optical probe. The nailfold of the second, third, fourth and fifth finger
was examined in each patient. According to Cutolo et al., patterns iden-
tified within the “SSc pattern” include: early, active and late (Cutolo et
al., 2006).
2.4. Clinical assessment
Modified Rodnan total skin score (mRSS) was chosen as the most
used method to assess skin induration in SSc. It is determined at a stan-
dardized location of 17 different sites of the body with a standardized
pinching method and it is scored from 0 to 3 (Clements et al., 1995).
Disease activity in SSc was measured using Disease Activity Index
(DAI), which consists of 10 weighted variables: total skin score N14,
scleroderma, digital necrosis, arthritis, total lung capacity b80%, eryth-
rocyte sedimentation rate (ESR) N30, hypocomplementemia and
change in cardiopulmonary, skin and vascular symptoms in the past
month (Valentini et al., 2001).
Disease severity was measured by Medsger Disease Severity Scale
(DSS). The original scale assessed disease severity in 9 organs or sys-
tems, namely general health, peripheral vascular, skin, joint/tendon,
muscle and gastrointestinal tract, lungs, heart and kidneys. Each
organ/system is scored separately from 0 to 4 depending on whetherthere is no, mild, moderate, severe or end-stage involvement
(Medsger et al., 1999).
2.5. ELISA for VEGF and endostatin
Serum VEGF levels were determined in SSc patients by commercial
ELISA kit (Human VEGF, Quantikine ELISA, R&D Systems, Minneapolis
MN), with a sensitivity of 9 pg/ml and an assay range of 31.2–
2000 pg/ml, according to the instructions provided by the manufactur-
er. After a 50-fold diluition, serum endostatin levels were determined in
SSc patients by commercial ELISA kit (Human Endostatin, Quantikine
ELISA, R&D Systems, Minneapolis MN), with a sensitivity of
0.063 ng/ml and an assay range of 0.3–10 ng/ml, according to the in-
structions provided by the manufacturer.
2.6. Doppler ultrasound
SSc patientswere placed for at least 15min before theDoppler ultra-
sound examination in a temperature-controlled room at 22 ± 0.4 °C.
The size of the left and right kidneys and the flow in the aorta and
renal arteries were evaluated to detect a morphologic abnormality or
renal artery stenosis. During the measurements, the patients were su-
pine and held their breath. Doppler ultrasound examinations were per-
formed by the same senior nephrologist blinded to the clinical features
of the patient. Renal Doppler ultrasoundwas performed using a Toshiba
Aplio Ultrasound System SSA-790 equipped with a convex 3.5-MHz
probe. Renal Dopplerflowwas obtained in 3 different interlobar arteries
of both kidneys (mesorenal, superior, and inferior pole), guided by
color-flow mapping. The Doppler gate width was kept small, and the
angle of insonation was maintained at b60°. We used an anterior ap-
proach for detecting the renal artery origin and an oblique, lateral ap-
proach for the intermediate tract and intrarenal vessels. No aliasing
was allowed in the interlobar arteries while the following parameters
were measured: peak systolic velocity (PSV), end diastolic velocity
(EDV), resistive index (RI), pulsatile index (PI), and systolic/diastolic
ratio (S/D). RI was calculated as (peak systolic frequency shift−mini-
mum diastolic frequency shift) / peak systolic frequency shift and the
PI was calculated as (peak systolic frequency shift / minimum diastolic
frequency shift) / mean frequency shift. The PSV and EDV are expressed
as cm/s. The mean value of 3 measurements of interlobar arteries from
each kidney was calculated. For each patient, Doppler ultrasound pa-
rameterswere calculated as themeanofmeasurements of both kidneys.
While performing the renal Doppler examination, the operator evaluat-
ed the heart function. The Doppler examination was not performed in
SSc patients with arrhythmia or tachycardia or bradycardia. Weighted
kappa was used to evaluate the intra rater reliability by the same
observer. The kappa values for RI and S/Dwere 0.971 and 0.975, respec-
tively. The intrapatient coefficient of variation for RI and S/D measure-
ment was 1.3% and 1.4%, respectively. Calcium-channel blocker
therapy was discontinued 72 h before the Doppler ultrasound (Rosato
et al., 2012). The mean references value for normal RI in adults is deter-
minate to be 0.60± 0.10, with 0.70 as upper limit of normal (Parolini et
al., 2009).
Patients receiving iloprost therapy underwent Doppler examination
the day before the next infusion.
2.7. Statistical analysis
The results were expressed as mean and standard deviation (SD) or
median and range, as appropriate. Commercially software (SPSS version
23.0) was used for statistical analysis. The coefficient of skewness and
the coefficient of kurtosis were used to evaluate the normal distribution
of data. Multiple regression analysis was applied to evaluate the rela-
tionship between Doppler indices of intrarenal arterial stiffness and
serum levels of VEGF and endostatin and the demographic and clinical
features (age, duration of disease, mRSS, DAI, DSS) and internal organ
Table 2
The mean value of serum UA and sCr, CKD-EPI, Doppler ultrasound indices in all SSc
patients.
SSc HC p
PI 1.43 ± 0.29 1.02 ± 0.16 p b 0.0001
43A. Gigante et al. / Microvascular Research 114 (2017) 41–45damage indices (creatinine, CKD-EPI, PAPs, DLCO, FVC). Pearson prod-
uct-moment or Spearman correlation coefficient (r) was used to test
for bivariate analysis. Group comparisons were made by Student's un-
paired 2-tailed t-test or the Kruskal-Wallis test, as appropriate. p-Values
b 0.05 were considered significant.RI 0.70 ± 0.06 0.51 ± 0.05 p b 0.0001
S/D 3.52 ± 0.79 2.11 ± 0.23 p b 0.0001
sCr 0.74 ± 0.18 0.68 ± 0.13 p N 0.05
CKD-EPI 94.1 ± 19 99.3 ± 9.5 p N 0.05
Serum UA 4.22 ± 1.12 4.14 ± 0.74 p N 0.05
IMT 0.75 ± 9 0.70 ± 13 p N 0.05
Systolic blood pressure (mm Hg) 112 ± 9 116 ± 12 p N 0.05
Diastolic blood pressure (mm Hg) 71 ± 6 75 ± 8 p N 0.05
BMI 23 ± 3.2 24 ± 4.2 p N 0.05
Uric acid (UA); serum creatinine (sCr); Chronic Kidney Disease Epidemiology Collabora-
tion (CKD-EPI); pulsatile index (PI); resistive index (RI); systolic/diastolic ratio (S/D), In-
timal media thickness (IMT).3. Results
The SSc patients' epidemiological and clinical features are showed in
Table 1. The Doppler indices of intrarenal arterial stiffness were signifi-
cantly (p b 0.0001) higher in SSc patients than HC. No significant differ-
ence of creatinine, serum uric acid and GFR was observed between SSc
patients and HC (Table 2). The medium values of serum VEGF and
endostatin were 283.4 ± 250.8 pg/ml and 118.1 ± 38.4 ng/ml,
respectively.
A significant positive correlation was observed between endostatin
and PI (r = 0.35, p b 0.0001), RI (r = 0.38, p b 0.0001) and S/D ratio
(r = 0.35, p b 0.0001) (Fig. 1). A negative correlation was observed be-
tween serum levels of endostatin and eGFR (r =−0.30, p b 0.01). No
significant (p N 0.05) correlationwas observed between VEGF and eGFR.
In the multiple regression analysis we analyzed Doppler indices of
intrarenal arterial stiffness as dependent variables (Table 3). In the anal-
ysis we observed a correlation betweenDoppler indices of intrarenal ar-
terial stiffness and age, eGFR, evaluated by CKD-EPI, and endostatin.
Only PI demonstrated a significant positive correlation with serum
levels of VEGF (r = 0.31, p b 0.01). A significant positive correlation
was observed between age and PI (r = 0.46, p b 0.0001), RI (r = 0.57,
p b 0.0001) and S/D ratio (r = 0.56, p b 0.0001). A significant negative
correlation was observed between eGFR and PI (r =−0.18, p b 0.05),
RI (r =−0.24, p b 0.05) and S/D ratio (r =−0.23, p b 0.05).
Using a cut-off value of 0.70 for RI, we grouped SSc patients in two
subgroups: normal RI (≤0.69) and high RI (≥0.70). In SSc patient with
high RI serum levels of endostatin are significantly (p b 0.01) higher
than in SSc patients with normal RI (129.4 ± 41.4 vs 105.3 ± 30.6)
(Fig. 2). No significant difference of serum levels of VEGF was observed
in SSc patients with normal or high RI.
The serum levels of endostatin (ng/ml) significantly (p b 0.01)
increased with progression of NVC damage: early (98.9 ± 40.9), active
(114.7 ± 35.5) and late (133.9 ± 33.9). The serum levels of VEGF
(pg/ml) did not show any significant (p N 0.05) difference in three
capillaroscopic groups of patients: early (274.4 ± 259.7), active
(268 ± 221.5) and late (305 ± 278). The serum levels of endostatin
(ng/ml) were significantly (p b 0.05) higher in SSc patients with digital
ulcers (DUs) than in SSc patients without DUs (127 ± 31.8 vs 107 ±
43.4) (Fig. 3). No significant (p N 0.05) difference of VEGF (pg/ml) was
observed in SSc with DUs (302± 244.8) or without DUs (259± 259.2).Table 1
SSc patients' epidemiological and clinical features.
Sex (female/male) 80/11
Age (years) 54.4 ± 13.3
Disease duration (years) 9 ± 6
DAI 2.8 ± 2.4
DSS 5 ± 3.2
dcSSc/lcSSc 47/44
Digital ulcers history 51 (56)
SSc-specific autoantibodies n (%)
Anti-topoisomerase I 50 (54.9)
Anti-centromere 37 (40.7)
None 4 (4.4)




Disease Activity Index (DAI); Disease Severity Scale (DSS); limited cutane-
ous SSc (lcSSc); diffuse cutaneous SSc (dcSSc).4. Discussion
Angiogenesis is characterized by the formation of new blood vessels
under control of angiogenesis inducers and inhibitors. It is well known
that in course of SSc the angiogenesis is impaired promoting disarrange-
ment of the microcirculation (Hummers et al., 2009).
In our study, serum VEGF and endostatin values are comparable to
data in the literature and, in particular, are higher in SSc patients
when compared to healthy population (Hummers et al., 2009; Farouk
et al., 2013; Hebbar et al., 2000; Distler et al., 2002).
Endostatin shows a positive correlation with intrarenal hemody-
namic parameters and, conversely, a negative correlation with eGFR.
Recent studies have suggested that endostatin is able to influence
the regulation of the extracellular and metalloproteinase matrix,
whichmay contribute to vascular remodeling in SSc (Peng et al., 2012).
Endostatin is an angiogenic inhibitor derived from type XVIII colla-
gen, which is particularly expressed in the fenestrated endothelium of
renal microcirculation (Lin et al., 2016).
In course of SSc elevated endostatin levels correlatewith skin sclero-
sis, cutaneous scars, digital ulcers (Hebbar et al., 2000), giant capillaries
in NVC (Distler et al., 2002), pulmonary arterial hypertension (PAH) and
SCR (Reiseter et al., 2015).
Reiseter et al. in an observational study have evaluated the serum
levels of endostatin and VEGF in unselected cohorts of 298 SSc patients
and 162 mixed connective tissue disease patients. Mean levels of
endostatin were increased in SSc patients when compared to HC. The
most vascular complications in course of disease like PAH and SRC
were associated with elevated endostatin levels. Furthermore,
endostatin resulted as only predictor of SRC and its high levels showed
a strong associationwith SScmortality during follow-up. The histopath-
ological features are related to endothelial dysfunction with intimal
thickening and fibrotic ‘onion-skinning’ of the interlobular and arcuate
renal arteries. Thus, Reiseter et al. hypothesize that dysregulated angio-
genesis may play a role in SRC in association to endostatin in the regu-
lation of matrix metalloproteinases and vascular remodeling (Reiseter
et al., 2015).
For this reasons some authors suppose that in SSc, during ischemic
manifestations (Hebbar et al., 2000), endostatin is over-expressed and
could establish a link between tissue collagen deposition and vascular
damage.
Also in CKD (Maeshima and Makino, 2010) and arterial hyperten-
sion (Marek-Trzonkowska et al., 2015) there is a dysbalance of angio-
genic and angiostatic factors. A simultaneous increase of angiogenic
inhibitor and reduction of pro-angiogenic factors occur in hypertensive
patients. Furthermore high levels of endostatin may determine micro-
vascular dysfunction with loss of terminal arterioles and capillaries
and increasing of peripheral resistance.
Similarly in our study, intrarenal hemodynamic parameters and
endostatin can increase in response to ischemic and hypoxic conditions.
Fig. 1. Correlation between serum levels of endostatin (ng/ml) and Doppler indices of intrarenal arterial stiffness or estimated glomerular filtration rate (CKD-EPI).
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ity in course of renal scleroderma-associated vasculopathy.
Rosato et al. have demonstrated that in the initial phases of SSc renal
injury, RI increases andmeasured GFR is normal or slightly reduced be-
cause is more linked to reduced blood inflow to intrarenal vessels than
reduced glomerular filtration capacity (Rosato et al., 2012).
Our results show a negative correlation between intrarenal arterial
stiffness (PI, RI, and S/D ratio) and eGFR. In fact, eGFR reduction is due
to intrarenal arteries blood inflow and to glomerular damage that oc-
curswith renal vascular progression. In a study conducted in elderly pa-
tients, endostatin showed a negative correlation with GFR and it was
associated with CKD progression (Ruge et al., 2014). Furthermore
other studies have demonstrated that in SSc renal vasculopathy, renal
functional reserve (Mohamed et al., 2010) is reduced as well as renalTable 3
Linear regression analysis models of correlations between intrarenal arterial stiffness and













RI Age 0.477 b0.001
CKD-EPI 0.259 b0.05
Endostatin 0.228 b0.01
S/D ratio Age 0.384 b0.05
CKD-EPI 0.247 b0.05
Endostatin 0.198 b0.05
Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI); pulsatile index (PI); resis-
tive index (RI); systolic/diastolic ratio (S/D); vascular endothelial growth factors (VEGF).blood flowwith high total renal vascular resistance. The possible mech-
anism is related to endothelium dysfunction, the hallmark of SSc, with
defective response to vasodilation with a tendency towards vasocon-
striction (Livi et al., 2002).
In this phase of disease, Doppler ultrasound assessment is a sensitive
and non invasive tool to evaluate the renal vascular damage. In aging
mice, endostatin has a profibrotic action inducing renal fibrosis. Lin et
al. have recently demonstrated in experimental aging animals high
levels of endostatin associated with microvascular rarefaction and pro-
gressive tubulointerstitial fibrosis (Lin et al., 2014).
On the other hand, intrarenal stiffness is not correlated to VEGF in
our study.Fig. 2. Serum levels of endostatin (ng/ml) in SSc patients with normal or high RI.
Fig. 3. Serum levels of endostatin (ng/ml) in tree capillaroscopic groups and in SSc patients with or without digital ulcers.
45A. Gigante et al. / Microvascular Research 114 (2017) 41–45Previously study suggested a biphasic regulation of VEGF. Chronic
hypoxia decreases VEGF levels, conversely in acute hypoxia VEGF levels
are increased (Olszewska-Pazdrak et al., 2009). In fact several studies
confirmed that when renal microcirculation is reduced also VEGF is de-
creased, as it occurs in chronic glomerulonephritis, ischemic nephropa-
thy, renal artery stenosis, chronic kidney diseases (Chade, 2011).
So, it is not surprising that in our study VEGF does not correlate with
intrarenal stiffness and renal function. In our study, the serum levels of
endostatin increase with the progression of capillaroscopic damage. In
addition, serum levels of endostatin are higher in SSc patients with
DUs than in SSc patients without DUs.
To the best of our knowledge, this is the first study that assesses
intrarenal hemodynamic parameters and endostatin in SSc patients.
As well as in digital damage, endostatin represents a marker of renal
scleroderma-associated vasculopathy.
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